Document 2588
 DOCN  M94A2588
 TI    Prevalence of gynecologic infections in a cohort of HIV-infected women.
 DT    9412
 AU    Spence M; Gagmon S; Cohn J; Harrison D; Brinson C; Stein A; Hellinger J
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):27 (abstract no. 083B). Unique
       Identifier : AIDSLINE ICA10/94369987
 AB    OBJECTIVE: To describe the prevalence of vaginal candidiasis (vc) and
       sexually transmitted diseases (STDs) in a broad based cohort of
       immunosuppressed HIV- infected women. METHODS: HIV-infected women in 6
       U.S. cities with a CD4 count < or = 500 and no recent history of
       cervical dysplasia were enrolled by their primary care physicians and
       questioned on their past and current sexual practices. History of
       gynecological infections was obtained and a complete pelvic examination
       was performed. RESULTS: Preliminary data are available on 86 of 126
       women enrolled. Median age of the population was 33 years (R, 20-52).
       Median number of sexual partners during the 6 months prior to study
       entry was only 1 (R, 0-4) compared to a median number of lifetime sexual
       partners of 10 (R, 1-1000). Eighty-three % had a history of vc.
       Twenty-one % had vc on pelvic examination including 30% of 20 patients
       receiving daily suppressive antifungal therapy during the past four
       weeks. Thirty-seven % had a history of trichomonas, 26% genital herpes
       (HSV), 26% gonorrhea (GC), 20% chlamydia, 19% pelvic inflammatory
       disease (PID) and 9% syphilis. Four % had trichomonas at the time of
       exam and 3% had HSV, but none had GC, chlamydia, PID or syphilis.
       CONCLUSION: The majority of immunosuppressed HIV-infected women have had
       vaginal candidiasis and at least one STD in addition to HIV. VC was the
       most prevalent gynecologic infection and was seen in 30% of patients
       receiving chronic suppressive antifungal therapy. Safer sex practices
       including fewer partners may explain the low prevalence of STDs in these
       patients.
 DE    Adult  Antifungal Agents/THERAPEUTIC USE  AIDS-Related Opportunistic
       Infections/*COMPLICATIONS  Candidiasis, Vulvovaginal/COMPLICATIONS/DRUG
       THERAPY  Female  Human  HIV Infections/*COMPLICATIONS  Middle Age  Sex
       Behavior  Sexually Transmitted Diseases/*COMPLICATIONS  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).